<info type="ChemicalEntity">N-(2-propylpentanoyl)urea</info> on <info type="OrganismTaxon">rats</info>.

The present study aimed to investigate the <info type="ChemicalEntity">anticonvulsant</info> activity as well as the effects on the level of <info type="GeneOrGeneProduct">hippocampal amino acid neurotransmitters</info> (<info type="GeneOrGeneProduct">glutamate</info>, <info type="GeneOrGeneProduct">aspartate</info>, <info type="GeneOrGeneProduct">glycine</info> and <info type="GeneOrGeneProduct">GABA</info>) of <info type="ChemicalEntity">N-(2-propylpentanoyl)urea</info> (<info type="ChemicalEntity">VPU</info>) in comparison to its parent compound, <info type="ChemicalEntity">valproic acid</info> (<info type="ChemicalEntity">VPA</info>). <info type="ChemicalEntity">VPU</info> was more potent than <info type="ChemicalEntity">VPA</info>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting <info type="OrganismTaxon">rats</info> against <info type="DiseaseOrPhenotypicFeature">pilocarpine-induced seizure</info> whereas the corresponding value for <info type="ChemicalEntity">VPA</info> was 322 mg/kg. In vivo microdialysis demonstrated that an intraperitoneal administration of <info type="ChemicalEntity">pilocarpine</info> induced a pronounced increment of <info type="GeneOrGeneProduct">hippocampal glutamate</info> and <info type="GeneOrGeneProduct">aspartate</info> whereas no significant change was observed on the level of <info type="GeneOrGeneProduct">glycine</info> and <info type="GeneOrGeneProduct">GABA</info>. Pretreatment with either <info type="ChemicalEntity">VPU</info> (50 and 100 mg/kg) or <info type="ChemicalEntity">VPA</info> (300 and 600 mg/kg) completely abolished <info type="DiseaseOrPhenotypicFeature">pilocarpine-evoked increases</info> in extracellular <info type="GeneOrGeneProduct">glutamate</info> and <info type="GeneOrGeneProduct">aspartate</info>. In addition, a statistically significant reduction was also observed on the level of <info type="GeneOrGeneProduct">GABA</info> and <info type="GeneOrGeneProduct">glycine</info> but less than a drastic reduction of <info type="GeneOrGeneProduct">glutamate</info> and <info type="GeneOrGeneProduct">aspartate</info> level. Based on the finding that <info type="ChemicalEntity">VPU</info> and <info type="ChemicalEntity">VPA</info> could protect the animals against <info type="DiseaseOrPhenotypicFeature">pilocarpine-induced seizure</info> it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of <info type="GeneOrGeneProduct">glutamate</info> and <info type="GeneOrGeneProduct">aspartate</info>. Therefore, like <info type="ChemicalEntity">VPA</info>, the finding that <info type="ChemicalEntity">VPU</info> could drastically reduce <info type="DiseaseOrPhenotypicFeature">pilocarpine-induced increases</info> in <info type="GeneOrGeneProduct">glutamate</info> and <info type="GeneOrGeneProduct">aspartate</info> should account, at least partly, for its <info type="ChemicalEntity">anticonvulsant activity</info> observed in <info type="DiseaseOrPhenotypicFeature">pilocarpine-induced seizure</info> in experimental animals. Some other mechanism than those being reported herein should be further investigated.